Mifamurtide

Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide has potential for use in rare disease and osteosarcoma research[1][2][3].

Product Specifications

CAS Number

[83461-56-7]

Product Name Alternative

MTP-PE; L-MTP-PE; CGP 19835

UNSPSC

12352211

Target

NOD-like Receptor (NLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/mifamurtide.html

Purity

99.58

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCCCCCCCCCCCCCCC(OC[C@@H](OC(CCCCCCCCCCCCCCC)=O)COP(OCCNC([C@@H](NC(CC[C@@H](NC([C@@H](NC([C@H](O[C@]([C@H](O)[C@H](O)CO)([H])[C@@H](NC(C)=O)C=O)C)=O)C)=O)C(N)=O)=O)C)=O)(O)=O)=O

Molecular Formula

C59H109N6O19P

Molecular Weight

1237.50

References & Citations

[1]Kevin Biteau, et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016 Feb 15;6 (3) :677-89.|[2]Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9 (2) : p. 131-5.|[3]Joseph F Cavallari, et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017 May 2;25 (5) :1063-1074.e3.|[4]Francesca Punzo, et al. Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells. Oncotarget. 2020 Feb 18;11 (7) :687-698.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C (Powder, stored under nitrogen)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

NOD2

Citation 01

AAPS PharmSciTech. 2024 Nov 26;25 (8) :272.|J Extracell Vesicles. 2025 Aug;14 (8) :e70152.|Res Sq. 2025 Jul 26.|The Ohio State University. 2023 Apr.|J Clin Invest. 2024 Oct 1;134 (22) :e179527.